title: Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism.
abstract: Feto-maternal microchimerism suggests that immunologic tolerance exists between mother and fetus. Based on this hypothesis, we performed haploidentical stem cell transplantation (SCT) without T-cell depletion (TCD) in 5 patients with advanced hematologic malignancies. HLA incompatibilities for graft-versus-host disease (GVHD) direction included 3-loci mismatches in 4 patients, and 2-loci mismatches in one patient. Recipient chimeric cells were detected in all patients. The prophylaxis against GVHD was tacrolimus with minidose methotrexate. Engraftment was obtained in all patients. An acute GVHD of less than or equal to grade 2 developed in all patients except one who developed tacrolimus encephalopathy. Two patients died, 1 from fungal pneumonia and 1 from disease progression. The other 3 patients survived, with one patient in complete remission. These observations suggest that haploidentical SCT based on the feto-maternal microchimerism without TCD is possible.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan. simazaki@koto.kpu-m.ac.jp
authors.forename: Chihiro
authors.initials: C
authors.lastname: Shimazaki
authors.forename: Naoya
authors.initials: N
authors.lastname: Ochiai
authors.forename: Ryo
authors.initials: R
authors.lastname: Uchida
authors.forename: Akira
authors.initials: A
authors.lastname: Okano
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Fuchida
authors.forename: Eishi
authors.initials: E
authors.lastname: Ashihara
authors.forename: Tohru
authors.initials: T
authors.lastname: Inaba
authors.forename: Naohisa
authors.initials: N
authors.lastname: Fujita
authors.forename: Etsuko
authors.initials: E
authors.lastname: Maruya
authors.forename: Masao
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000293:Adolescent; D000328:Adult; D002678:Chimera / Q000276:immunology*; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000276:immunology; D006680:HLA Antigens / Q000235:genetics*; D006239:Haplotypes / Q000235:genetics; D006648:Histocompatibility; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007239:Infections; D007938:Leukemia / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008297:Male; D008431:Maternal-Fetal Exchange; D009035:Mothers; D036102:Peripheral Blood Stem Cell Transplantation; D011247:Pregnancy; D012074:Remission Induction; D035781:Siblings; D014184:Transplantation, Homologous / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens